On September 5, the 22nd Summer Summit of the Yabuli China Entrepreneurs Forum (hereinafter referred to as Yabuli Forum) 2026 opened in Chengdu with the theme "Corporate Innovation and Overcoming Cycles".

From September 8 to 9, the 2026 Shanghai International Pharma-Health Innovation and Capital Conference and the 15th Pharma CEO Forum were held in Shanghai.

On September 28, SBP Group (01177.HK) announced that its core subsidiary, Chia Tai Tianqing Pharmaceutical Group (CTTQ), has entered into a strategic biosimilars partnership with STADA Arzneimittel AG (STADA), a leading European healthcare and pharmaceuticals company.

Recently, CTTQ (Chia Tai Tianqing), a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 01177.HK), signed an agreement with the National Natural Science Foundation of China (NSFC) to contribute 100 million RMB to participate in the Joint Fund for Innovation and Development of Private Enterprises of the National Natural Science Foundation (hereinafter referred to as the "Joint Fund").